Stemline Therapeutics (STML) – Press Releases
-
Menarini Group Completes Acquisition of Stemline Therapeutics
-
SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations
-
STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm
-
SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations
-
Menarini Group to Acquire Stemline Therapeutics in Transaction Valued at Up to $677 Million
-
Stemline Therapeutics Reports Fourth Quarter 2019 Financial Results
-
Stemline Therapeutics to Host Conference Call on Fourth Quarter 2019 Financial Results on March 16, 2020
-
Stemline Therapeutics to Present at the Cowen 40th Annual Health Care Conference
-
Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers
-
Stemline Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
-
Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meetin
-
Stemline Therapeutics Names Robert M. Francomano Chief Commercial Officer
-
Stemline Therapeutics Highlights Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
-
Stemline Therapeutics to Present at Piper Jaffray’s 31st Annual Healthcare Conference
-
Stemline Therapeutics Reports Third Quarter 2019 Financial Results
-
Stemline Therapeutics Announces Three ELZONRIS Presentations, Including an Oral Presentation in Myelofibrosis, at Upcoming ASH Meeting
-
Stemline Therapeutics to Host Conference Call on Third Quarter 2019 Financial Results on November 8, 2019
-
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Japanese Society of Hematology
-
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress
-
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress
-
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference
-
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference
-
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
-
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference
-
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock
-
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
-
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®
-
Stemline Therapeutics Reports Second Quarter 2019 Financial Results
-
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019
-
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting
-
Stemline Therapeutics Announces Presentation of ELZONRIS (tagraxofusp) Preclinical Data in Systemic Sclerosis, an Autoimmune Disorder, at EULAR Congress
-
Stemline Therapeutics Announces Three ELZONRIS (tagraxofusp) Clinical Presentations at EHA Congress June 13-15
-
Stemline Therapeutics Announces ASCO Presentation of ELZONRIS Phase 2 Clinical Data in CMML and MF; Provides Next Steps for CMML Program
-
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at Upcoming EHA Annual Congress
-
Stemline Therapeutics Announces ELZONRIS Clinical Data Selected for Presentation at the Upcoming ASCO Annual Meeting
-
Stemline Therapeutics Reports First Quarter 2019 Financial Results
-
Stemline Therapeutics to Host Conference Call on First Quarter 2019 Financial Results on May 10, 2019
-
Stemline Therapeutics Announces New England Journal of Medicine Publication of ELZONRIS (tagraxofusp) Pivotal Study Results
-
Stemline Therapeutics to Participate in Panel on Myeloid Tumors at the 31st Annual ROTH Conference
-
Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results
-
Stemline In-Licenses Worldwide Rights to Novel Selective RET Inhibitor (SL-1001); Expands Oncology Pipeline
-
Stemline Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference
-
Stemline Therapeutics Announces Validation of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA)
-
Consolidated Research: 2019 Summary Expectations for Marriott International, Calavo Growers, Kinsale Capital Group, Fluidigm, Goldman Sachs BDC, and Stemline Therapeutics — Fundamental Analysis, Key
-
Stemline Therapeutics Closes $92 Million Public Offering of Common Stock
-
Stemline Therapeutics Announces Upsizing and Pricing of $80 Million Public Offering of Common Stock
-
Stemline Therapeutics Announces Proposed Public Offering of Common Stock
-
Stemline Therapeutics Announces Submission of European Marketing Authorization Application (MAA) for ELZONRIS™
-
Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
-
FDA Approves ELZONRIS™ (tagraxofusp), the First Treatment for Blastic Plasmacytoid Dendritic Cell Neoplasm and First CD123-Targeted Therapy
Back to STML Stock Lookup
